About this trial
The current study proposal aims to investigate the clinical practice variation of the initial use of avacopan for AAV patients in Europe. The study will describe patient characteristics and organ-specific clinical benefit of avacopan treatment in a unique, first-experience cohort of AAV patients. By studying the clinical practice variation of first-experience avacopan treatment, this study will be uniquely positioned to identify pivotal issues on the real-life implementation of avacopan treatment. These observational data can ultimately serve to address current knowledge gaps on avacopan treatment in AAV patients, improve the care and drug-access for AAV patients with avacopan treatment and generate new areas of research.
Eligibility criteria
Qualifiers
Established diagnosis of GPA or MPA
Treatment (initiation) with avacopan
Informed consent for use of medical data
Disqualifiers
If there is no AAV disease activity present that can be supported by an objectifiable clinical measure or assessment
If a subject is below 16 years old
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Leiden University Medical Center
Lead sponsor
University of Udine
Collaborator
University of Modena and Reggio Emilia
Collaborator
Hospital Universitari de Bellvitge
Collaborator
ZOL Hospital Genk Belgium
Collaborator